nepodin: isolated from Rumex crispus
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Rumex | genus | A plant genus of the family POLYGONACEAE that contains patientosides and other naphthalene glycosides.[MeSH] | Polygonaceae | The only family of the buckwheat order (Polygonales) of dicotyledonous flowering plants. It has 40 genera of herbs, shrubs, and trees.[MeSH] |
Rumex crispus | species | [no description available] | Polygonaceae | The only family of the buckwheat order (Polygonales) of dicotyledonous flowering plants. It has 40 genera of herbs, shrubs, and trees.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 100780 |
CHEMBL ID | 508681 |
CHEBI ID | 7520 |
SCHEMBL ID | 1673268 |
MeSH ID | M0588423 |
Synonym |
---|
nsc-365795 |
nsc365795 |
1-(1,8-dihydroxy-3-methylnaphthalen-2-yl)ethanone |
nepodin |
C09954 |
3785-24-8 |
musizin |
AC1L2PGU , |
dianellidin |
CHEMBL508681 |
chebi:7520 , |
bdbm50015232 |
nsc 365795 |
unii-xst9srr6x4 |
1-(1,8-dihydroxy-3-methyl-2-naphthalenyl)ethanone |
xst9srr6x4 , |
ethanone, 1-(1,8-dihydroxy-3-methyl-2-naphthalenyl)- |
1-(1,8-dihydroxy-3-methyl-naphthalen-2-yl)-ethanone |
FS-2009 |
AKOS022652018 |
1-(1,8-dihydroxy-3-methyl-2-naphthyl)ethanone |
SCHEMBL1673268 |
DTXSID00191280 |
1-(1,8-dihydroxy-3-methyl-2-naphthalenyl)-ethanone |
F17724 |
FT-0766971 |
mfcd00238579 |
2-acetyl-1,8-dihydroxy-3-methylnaphthalene |
2'-acetonaphthone, 1',8'-dihydroxy-3'-methyl- |
musizine |
Q27107521 |
1-(1,8-dihydroxy-3-methylnaphthalen-2-yl)ethan-1-one |
CS-0032082 |
HY-N5018 |
1-(1,8-dihydroxy-3-methyl-naphthalen-2-yl)ethanone |
AC-34739 |
Class | Description |
---|---|
naphthols | Any hydroxynaphthalene derivative that has a single hydroxy substituent. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Prostaglandin G/H synthase 1 | Ovis aries (sheep) | IC50 (µMol) | 27.4300 | 0.0003 | 2.1774 | 10.0000 | AID1141756 |
Prostaglandin G/H synthase 2 | Ovis aries (sheep) | IC50 (µMol) | 32.2800 | 0.0010 | 1.4539 | 10.0000 | AID1141757 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID355624 | Cytotoxicity against human HT-29 cells | |||
AID1141755 | Inhibition of ovine COX2 using arachidonic acid as substrate at 30 uM preincubated for 10 mins before substrate addition measured after 5 mins by EIA | 2014 | European journal of medicinal chemistry, Jun-10, Volume: 80 | Synthesis, biological evaluation, molecular docking and theoretical evaluation of ADMET properties of nepodin and chrysophanol derivatives as potential cyclooxygenase (COX-1, COX-2) inhibitors. |
AID1082590 | Antifungal activity against Blumeria graminis f. sp. hordei assessed as control of barley powdery mildew treated 1 day before inoculation | 2011 | Journal of agricultural and food chemistry, Nov-23, Volume: 59, Issue:22 | Potent in vivo antifungal activity against powdery mildews of pregnane glycosides from the roots of Cynanchum wilfordii. |
AID355625 | Cytotoxicity against human KBMRI cells | |||
AID1141757 | Inhibition of ovine COX2 using arachidonic acid as substrate preincubated for 10 mins before substrate addition measured after 5 mins by EIA | 2014 | European journal of medicinal chemistry, Jun-10, Volume: 80 | Synthesis, biological evaluation, molecular docking and theoretical evaluation of ADMET properties of nepodin and chrysophanol derivatives as potential cyclooxygenase (COX-1, COX-2) inhibitors. |
AID355622 | Antitumor activity against Agrobacterium tumefaciens-induced crown gall tumors in potato tubers by potato disk test | |||
AID355621 | Toxicity in brine shrimp | |||
AID1141758 | Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2 | 2014 | European journal of medicinal chemistry, Jun-10, Volume: 80 | Synthesis, biological evaluation, molecular docking and theoretical evaluation of ADMET properties of nepodin and chrysophanol derivatives as potential cyclooxygenase (COX-1, COX-2) inhibitors. |
AID1141756 | Inhibition of ovine COX1 using arachidonic acid as substrate preincubated for 10 mins before substrate addition measured after 5 mins by EIA | 2014 | European journal of medicinal chemistry, Jun-10, Volume: 80 | Synthesis, biological evaluation, molecular docking and theoretical evaluation of ADMET properties of nepodin and chrysophanol derivatives as potential cyclooxygenase (COX-1, COX-2) inhibitors. |
AID1141754 | Inhibition of ovine COX1 using arachidonic acid as substrate at 30 uM preincubated for 10 mins before substrate addition measured after 5 mins by EIA | 2014 | European journal of medicinal chemistry, Jun-10, Volume: 80 | Synthesis, biological evaluation, molecular docking and theoretical evaluation of ADMET properties of nepodin and chrysophanol derivatives as potential cyclooxygenase (COX-1, COX-2) inhibitors. |
AID355623 | Cytotoxicity against human A549 cells | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.76) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |